YouTube Facebook LinkedIn Google+ Twitter Xingrss  

Generic Drug Debates


March 6, 2012 | A feature of Obama's health care plan was cheaper generic drug options, but that's proving easier said than done. Approving biosimilars is a complex and drawn-out process, and an "interchangable" classification is still under debate. FDA will hold a hearing on May 11 to review the label. The discount percentage is also unclear, with numbers ranging from 10% to 90% off branded products. Huffington Post
View Next Related Story
Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1


For reprints and/or copyright permission, please contact  Terry Manning, 781.972.1349 , tmanning@healthtech.com.